Palo Alto-based Founder Institute is launching its Houston program at Station Houston. Image courtesy Founder Institute

Silicon Valley-based Founder Institute has announced its second Texas program in Houston, which will operate out of Station Houston. Founder Institute Houston applications for the inaugural cohort close May 19.

The early stage accelerator focuses on advancing startup companies in the pre-funding phase.

"It's quite different from any other program in Houston currently," says Neal Murthy, director of Founder Institute Houston. "It's an accelerator, but it's an idea-stage accelerator."

Before Founder Institute, Houston's only early stage opportunities were tied to universities — like the University of Houston's Red Labs or Rice University's Owl Spark — and those are typically focused on the university's community and on education, Murthy says.

In anticipation of launch, Founder Institute Houston will host a series of free entrepreneurial events, with the first one being March 19.

The Houston chapter will be ran by three directors: Murthy, a UH lecturer and angel investor, James Phelan, innovation expert with a real estate background, and Tabbie Saenz, Alice community leader and Baker Ripley mentor. Martin Martinez, managing director of Founder Institute Texas, who launched the Austin program, will also join the team.

"What's nice about our team is because we were already colleagues and friends prior to coming together on this project, we already have rapor, we can communicate, and we know each other's working styles, strengths, and weaknesses," says Phelan.

Founded in 2009 by Adeo Ressi and Jonathan Greechan, Founder Institute has chapters in 180 cities in 65 countries. They've contributed to 3,500 companies that have now raised over $800 million.

"Houston's supportive startup community and its affordable living costs have inspired a lot of entrepreneurial enthusiasm in the city. Every year, more co-working spaces and incubators move to Houston and it's now easier to launch a startup here than ever before. We aim to help that trend," Ressi says in a release. "I believe that our structured accelerator program will give potential founders the guidance they need to launch successful technology companies in Houston."

Every chapter focuses on the same idea-stage type of company and selects around 30 companies to participate in a 14-week course of education, mentorship, and business development. The cohort spends around three hours a week in educational programming, but then is expected to spend 20 to 25 hours a week working assignments and business development. It's designed to be tough. Usually, only around 10 founders of the 30 will cross the finish line.

"If they can't handle this course, then there's no way they're going to be a successful founder because this course is a breeze compared to running a company," says Phalen.

The Founder Institute alumni network is huge, and is one of the program's biggest perks. Not only do participants get access to a network successful founders, but they also usually have a foot in the door at the next stage of competitive accelerator programs.

"That's an enormously valuable thing from a fundraising aspect if you have the support from another successful founder standing next to you, vouching for you," Phelan says.

Another thing that makes Founder Institute different is, rather than operating off an equity approach, Founder Institute and its local directors receive warrants from each participating company. And, fellow founders and even program mentors receive a cut too.

"The sharing of that [means] everyone has economic incentives and it encourages collaboration among the cohort itself," Murthy says.

Founder Institute's expansion plan for Texas doesn't end at Austin and Houston. Two other locations in Dallas and San Antonio are also in route to the Lone Star State. However, Houston's a bit different of a city to be in, with it's diversity and large size.

"We are going to be targeting a very diverse community as well. We want to have everyone who hasn't had a chance to access resources like this," Saenz says.

Murthy, who has been a mentor for the Founder Institute in Austin, says it's so remarkable to see how much these founders accomplish in the 14 weeks, and he can't wait to see that affect the Houston ecosystem.

"We think that Houston needs a number of new elements to fill out its ecosystem, and this is one of them — an idea-stage accelerator," Murthy says. "We've seen the success it's had in Austin and globally, and we're hoping to bring that to Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.